134 related articles for article (PubMed ID: 11107384)
1. Thalidomide.
Waldman AR
Clin J Oncol Nurs; 2000; 4(2):99-100. PubMed ID: 11107384
[No Abstract] [Full Text] [Related]
2. Thalidomide--a revival story.
Raje N; Anderson K
N Engl J Med; 1999 Nov; 341(21):1606-9. PubMed ID: 10564693
[No Abstract] [Full Text] [Related]
3. Is thalidomide a true anti-angiogenic molecule in multiple myeloma?
Ribatti D; Vacca A
Haematologica; 2002 Apr; 87(4):344-5. PubMed ID: 11940476
[No Abstract] [Full Text] [Related]
4. Thalidomide: present and future in multiple myeloma.
Hussein MA
Expert Rev Anticancer Ther; 2005 Feb; 5(1):25-31. PubMed ID: 15757435
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide in the treatment of multiple myeloma.
Rajkumar SV
Expert Rev Anticancer Ther; 2001 Jun; 1(1):20-8. PubMed ID: 12113124
[TBL] [Abstract][Full Text] [Related]
6. On the use of thalidomide as an antiangiogenic agent in the treatment of multiple myeloma.
Ribatti D; Vacca A
Ann Hematol; 2003 Apr; 82(4):262. PubMed ID: 12707735
[No Abstract] [Full Text] [Related]
7. [Thalidomide--new prospective therapy in oncology].
Pałgan K; Pałgan I
Wiad Lek; 2003; 56(9-10):455-9. PubMed ID: 15049211
[TBL] [Abstract][Full Text] [Related]
8. Thalidomide--a treatment for cancer?
Mayo Clin Health Lett; 2000 Jun; 18(6):4. PubMed ID: 10868128
[No Abstract] [Full Text] [Related]
9. Thalidomide shows promise as cancer treatment.
Health News; 2000 Jan; 6(1):8. PubMed ID: 11019665
[No Abstract] [Full Text] [Related]
10. [Thalidomide and others: new treatment for myeloma].
Malphettes M; Fermand JP
Rev Prat; 2003 Oct; 53(15):1633-5. PubMed ID: 14689905
[No Abstract] [Full Text] [Related]
11. [Multiple myeloma: the role of angiogenesis and therapeutic application of thalidomide].
Jurczyszyn A; Wolska-Smoleń T; Skotnicki AB
Przegl Lek; 2003; 60(8):542-7. PubMed ID: 14974349
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of thalidomide in the treatment of multiple myeloma.
Warzocha K; Kraj M; Pogłód R; Szpila T; Mendek-Czajkowska E; Chełstowska M; Tronina RH
Acta Pol Pharm; 2008; 65(6):771-4. PubMed ID: 19172865
[No Abstract] [Full Text] [Related]
13. [Thalidomide for the treatment of refractory multiple myeloma].
Kakimoto T; Hattori Y; Okamoto S
Rinsho Ketsueki; 2002 May; 43(5):345-8. PubMed ID: 12096483
[No Abstract] [Full Text] [Related]
14. Why not start with thalidomide?
Loprinzi C; Rajkumar SV
J Clin Oncol; 2003 Jun; 21(11):2211-4. PubMed ID: 12775748
[No Abstract] [Full Text] [Related]
15. [Bone marrow angiogenesis in multiple myeloma: new insights into the pathogenesis, and development of a new therapeutic approach].
Hattori Y; Kakimoto T
Rinsho Ketsueki; 2000 May; 41(5):426-9. PubMed ID: 10879105
[No Abstract] [Full Text] [Related]
16. Low-dose of thalidomide in the treatment of refractory myeloma.
Pini M; Baraldi A; Pietrasanta D; Allione B; Depaoli L; Salvi F; Levis A
Haematologica; 2000 Oct; 85(10):1111-2. PubMed ID: 11025615
[No Abstract] [Full Text] [Related]
17. The revitalization of thalidomide.
Thomas DA; Kantarjian HM
Ann Oncol; 2001 Jul; 12(7):885-6. PubMed ID: 11521791
[No Abstract] [Full Text] [Related]
18. [Thalidomide: (re)discovery of a not very dear old molecule].
Bressoud A; Schwab BZ
Rev Med Suisse Romande; 2003 Apr; 123(4):238-40. PubMed ID: 15088555
[TBL] [Abstract][Full Text] [Related]
19. Early changes in bone marrow morphology induced by thalidomide in refractory myeloma patients.
Corso A; Lorenzi A; Zappasodi P; Invernizzi R; Vanelli L; Lazzarino M
Haematologica; 2003 Aug; 88(8):958-60. PubMed ID: 12935985
[No Abstract] [Full Text] [Related]
20. [An old drug as a carcinostatic. The new career of thalidomide].
Holzgrabe U
Pharm Unserer Zeit; 2007; 36(6):446-9. PubMed ID: 17957689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
